Background: High-sensitivity cardiac troponin testing is used to detect myocardial damage in patients with acute chest pain. Heart-type fatty acid binding protein (H-FABP) may be an alternative, available as point-of-care test. Methods: Patients (n=203) referred by general practitioners for suspected acute coronary syndrome or presenting with typical chest pain and one major cardiovascular risk factor at the emergency department were prospectively included in a single-centre cohort study. High-sensitivity cardiac troponin T (hs-TnT) and point-of-care H-FABP testing were concomitantly performed at admission and after 6h. Results: Maximal hs-TnT levels above the 99th percentile were observed in 152 patients (75%) with 127 (63%) fulfilling criteria for myocardial infarction. Upon admission, hs-TnT and H-FABP were associated with an area under the curve (95% CI) of 0.83 (0.77-0.89) and 0.79 (0.73-0.85), respectively, to predict myocardial infarction, which increased to 0.93 (0.90-0.97) and 0.88 (0.84-0.93), respectively, after 6h. The diagnostic accuracy for non-ST-segment elevation myocardial infarction was somewhat lower with an area under the curve (95% CI) of 0.80 (0.72-0.87), 0.90 (0.84-0.96), 0.73 (0.64-0.81) and 0.77 (0.67-0.86), respectively. When assessment was performed within 3h of chest pain onset, diagnostic accuracy of H-FABP versus hs-TnT was similar. Each standard deviation increase in admission H-FABP was associated with a 68% relative risk increase of all-cause mortality (p-value=0.027) during 666±155 days of follow-up. Conclusions: Point-of-care H-FABP testing has lower diagnostic accuracy compared with hs-TnT assessment in patients with high pre-test acute coronary syndrome probability, but might be of interest when assessment is possible early after chest pain onset.
Introduction
Chest pain is a common complaint in patients presenting at the emergency department. 1 Excluding an acute coronary syndrome (ACS) is a primary objective and depends on pre-test probability assessment, electrocardiographic findings and biomarker measurements. High-sensitivity cardiac troponin I or T assays have emerged as the preferred biomarker tests for detection of myocardial damage and have become invaluable in the diagnosis of acute myocardial infarction. [2] [3] [4] [5] However, limitations of cardiac troponin testing include a relatively low sensitivity in the first 0-6 h immediately after onset of chest pain and low specificity for acute myocardial infarction because other causes (e.g. chronic kidney disease) may also result in increased values. Additionally, rapid high-sensitivity point-of-care tests for cardiac troponin are not available yet for primary care physicians, resulting in frequent referral of patients with suspected ACS to the hospital. Heart-type fatty acid binding protein (H-FABP) is an alternative biomarker for detection of myocardial damage which may overcome some of these limitations. 6 H-FABP is a small unbound protein (12 kDa) , present at high concentrations in the myocardial cytoplasm, and released within minutes into the systemic circulation in the case of myocardial ischaemia. 7 Similar to cardiac troponins, its elimination from the plasma is mainly by renal excretion. Interestingly, H-FABP assessment is possible as a rapidly available point-of-care test. 8, 9 The aim of this study was to compare the diagnostic and prognostic value of a contemporary H-FABP point-of-care test (FABPulous BV, Maastricht, the Netherlands) with high-sensitivity cardiac troponin T (hs-TnT) testing in a population of patients presenting at the emergency department with a chief complaint of chest pain and high pre-test probability for ACS.
Methods

Study design
This prospective single-centre cohort study was conducted at a tertiary care hospital (Ziekenhuis Oost-Limburg, Genk, Belgium) from March 2012 until March 2013. The study was commissioned by FABPulous BV (Maastricht, the Netherlands), who provided an unrestricted research grant. The company was not involved in the data collection, analysis, or writing of the manuscript, but had the opportunity to review the final version before submission and make additional recommendations. This investigation conforms to the principles outlined in the Declaration of Helsinki and the locally appointed ethics committee has approved the study protocol. Written informed consent was obtained from every patient at the moment of inclusion in the study. All authors had full access to the data and contributed to the writing of the manuscript. Together, they take responsibility for the integrity of the data and agree to the report as written.
Study population
Study patients were 18 years of age or older and presented with chest pain at the emergency department. To be eligible for study inclusion, they either had to be referred by a general practitioner for suspected ACS, or suffer from typical chest pain according to the treating cardiologist in the presence of at least one major cardiovascular risk factor (current smoking, diabetes, arterial hypertension and/or dyslipidaemia). Exclusion criteria were: (1) time since onset of chest pain >24 h; (2) repeat inclusion in the study; and (3) inability to provide written informed consent.
Study protocol
At presentation, patients immediately underwent routine clinical examination and a 12-lead electrocardiogram. A venous blood sample was obtained for assessment of hs-TnT plasma levels. Management was instituted according to the most recent European Society of Cardiology guidelines at the time given. 10, 11 Briefly, all patients received 250 mg of aspirin and 70 IU heparin per kg body weight (maximal 5000 IU) at the emergency department when a tentative diagnosis of ACS was made. Dual antiplatelet therapy was used in all patients with confirmed ACS according to the treating cardiologist, with a loading dose of the P2Y 12 -inhibitor preferably given at first presentation in the emergency department. ST-segment elevation myocardial infarction patients received a 60 mg loading and 10 mg maintenance dose of prasugrel. Others received a 600 mg loading and 75 mg maintenance dose of clopidogrel. In the case of a primary percutaneous coronary intervention (PCI), bolus bivalirudin at a dose of 0.75 mg/kg was given, followed by an infusion at 1.75 mg/ kg per h. Blood samples for biomarker assessment were taken immediately after PCI, 6 h later and again after 15 h. Thereafter, daily samples were taken until hs-TnT values decreased for at least two consecutive samples. H-FABP point-of-care testing was performed concomitantly with the first three blood samples.
Biomarker measurements
Venous blood samples for hs-TnT assessment were collected in heparin-coated vacutainer tubes. hs-TnT was measured using the Elecsys Cobas 5th Generation hs-TnT assay (Roche Diagnostics, F Hoffmann-La Roche Ltd, Basel, Switzerland). The 99th percentile upper limit of normal is 14 ng/l for this assay, with a coefficient of variation <10% at 9 ng/l. 12 H-FABP was measured at the bedside using the point-of-care H-FABP test developed by FABPulous BV. This test uses a droplet of whole blood obtained from a finger prick and has a detection limit of 0.5 µg/l with a 99th percentile upper limit of normal equal to 5.3 µg/l. 13 
Study end-points
The predictive value of point-of-care H-FABP testing versus hs-TnT assessment was evaluated for myocardial infarction as well as for the combined end-point of any cardiac diagnosis (myocardial infarction, unstable angina, stable angina, ventricular arrhythmia, myocarditis, Tako-Tsubo cardiomyopathy, atrial fibrillation/flutter or pericarditis) or pulmonary embolism. Myocardial infarction was defined according to its third universal definition as a dynamic rise in hs-TnT levels with a peak value above the 99th percentile (>14 ng/l) accompanied by any of the following: (1) development of new pathological Q-waves on the electrocardiogram; (2) abnormal repolarization changes or new left bundle branch block with imaging evidence of new regional wall abnormality; or (3) identification of an intracoronary thrombus on coronary angiography. 14 All final diagnoses were independently confirmed by two authors (FHV and PV), with a consensus decision made in the case of disagreement. Sensitivity analysis was performed by excluding all patients presenting with ST-segment elevation myocardial infarction. Alternatively, results were stratified according to the duration of chest pain since onset (0-180 min; 180-360 min; 360-720 min; 720-1440 min; and >1440 min) and presence or absence of chronic kidney disease, defined as an estimated glomerular filtration rate <60 ml/min per 1.73m² according to the Chronic Kidney Disease Epidemiology Collaboration formula. 15 Finally, time to all-cause mortality was analysed as a clinical end-point.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation if normally distributed or otherwise by median (interquartile range (IQR)). Normality was assessed by the Shapiro-Wilk statistic. Categorical variables are expressed as percentages. Receiver operating characteristic (ROC) curve analysis with nonparametric distribution assumption was used to compare the predictive value of H-FABP versus hs-TnT for myocardial infarction and the combined end-point of any cardiac diagnosis or pulmonary embolism. Discriminant analysis was conducted to evaluate the added value of combining both biomarker assessments for the diagnosis of myocardial infarction. Because both hs-TnT and H-FABP were not normally distributed, values were log-transformed for this analysis. The discriminant score was used to calculate the combined predictive value of hs-TnT and point-of-care H-FABP with the optimal cut-off determined from the ROC curve. The Cox proportional hazards model was used to calculate hazard ratios with corresponding 95% confidence intervals (95% CIs) for allcause mortality. Statistical significance was always set at a two-tailed probability level of <0.05. All statistics were performed using IBM ® SPSS ® (version 22.0) for Windows.
Results
Study population
Two hundred and twenty-one patients were screened for participation in the study. Four patients were excluded because chest pain onset was >24 h. Fourteen patients had missing H-FABP data and were therefore omitted from the current analyses. Consequently, the final study population comprised 203 patients with complete data. Baseline characteristics are summarized in Table 1 . Thirty percent of patients were referred by a general practitioner for suspected ACS. Overall, the prevalence of cardiovascular risk factors was high, resulting in a high pre-test probability for ACS.
Hospital stay and final diagnosis
The median (IQR) duration of hospital stay was four (2-6) days. A maximal hs-TnT level above the 99th percentile (>14 ng/l) was observed in 152 patients (75%) with 127 patients (63%) fulfilling criteria for myocardial infarction. Maximal hs-TnT and creatine kinase levels in patients qualifying for this diagnosis were 964 (233-3216) ng/l and 545 (227-1371) U/l, respectively. Electrocardiographic features at presentation and results of the coronary angiography in the whole population are reported in Table 2 . Percutaneous coronary intervention was performed in 106 patients (52%), while seven (6%) were referred for urgent coronary artery bypass surgery. A list of the final diagnoses in the study population is presented in Table 3 . Table 4 presents the sensitivity, specificity, positive and negative predictive value of hs-TnT, point-of-care H-FABP and their combined assessment for a diagnosis of myocardial infarction, using the 99% upper limit of normal cut-offs for both biomarkers (14 ng/l and 5.3 µg/l, respectively). At these cut-offs point-of-care H-FABP lacked sensitivity when compared with hs-TnT, but was somewhat more specific. Discriminant analysis showed that combined biomarker assessment over hs-TnT alone increased correct classification of crossvalidated grouped cases from 85.5% to 88% at the second time-point (after 6 h), without any improvement in reclassification at the first (admission) or third timepoint (after 15 h).
Diagnostic accuracy of H-FABP versus hs-TnT assessment
Combining H-FABP and hs-TnT assessment
Diagnostic accuracy of H-FABP versus hs-TnT assessment in prespecified subgroups
After pooling all biomarker measurements and stratifying according to the time since onset of chest pain, H-FABP versus hs-TnT demonstrated similar diagnostic accuracy for myocardial infarction in the case of early assessment (0-180 min), while hs-TnT outperformed point-of-care H-FABP testing thereafter (Figure 1 ). Within the first 180 min, H-FABP had 94% sensitivity to exclude myocardial infarction at a cut-off equal to 2.4 µg/l, similar to hs-TnT at a cut-off of 5 ng/l. At admission, hs-TnT levels better predicted myocardial infarction when compared with pointof-care H-FABP measurements in patients without chronic kidney disease (AUC (95% CI) = 0.88 (0.82-0.93) versus 0.83 (0.77-0.90), respectively). In contrast, both biomarkers performed similarly and poorly in patients with chronic kidney disease (AUC (95% CI) = 0.68 (0.52-0.83) versus 0.69 (0.53-0.84), respectively).
Prognostic value of H-FABP point-of-care assessment
Total follow-up was 666 ± 155 days, during which 11 patients (5%) died. Each standard deviation increase in admission H-FABP was associated with a hazard ratio (95% CI) of 1.68 (1.06-2.65) for all-cause mortality (p-value=0.027). After correction for age and gender, the increased risk for all-cause mortality was still highly significant (hazard ratio (HR) (95% CI) = 1.99 (1.20-3.31); p-value=0.008). This remained true even after extensive adjustments for age, gender, cardiovascular risk factors and baseline renal function (HR (95% CI) = 2.65 (1.40-5.03); p-value=0.003). In contrast admission hs-TnT levels were 
Discussion
This study offers further insight into the potential use of point-of-care H-FABP testing in patients presenting at the emergency department with typical chest pain suspect for ACS. In general, point-of-care H-FABP testing did not provide incremental diagnostic information over hs-TnT assessment, with the latter being more accurate at hospital admission as well as after 6 h and 15 h. In addition, combining both hs-TnT and point-of-care H-FABP assessment did not substantially improve diagnostic accuracy. Interestingly, when performed early within 180 min after chest pain onset, point-of-care H-FABP testing excluded myocardial infarction with similar certainty to hs-TnT assessment. These findings might be of particular interest to general practitioners who are often faced with patients suffering from acute-onset chest pain and a low probability of advanced coronary artery disease. It might be appealing to conduct further studies of point-of-care H-FABP testing in this particular population. Finally, admission H-FABP but not admission hs-TnT was strongly and independently associated with all-cause mortality in a population with a high pre-test probability for ACS. It has been shown that H-FABP levels rise as early as 15 min after onset of a myocardial infarction. 16 Because conventional cardiac troponin assays have limited sensitivity to exclude myocardial infarction in patients presenting with chest pain during that early time window, it has been proposed that H-FABP testing might provide a useful addition to rule in or rule out this diagnosis in the emergency department. Moreover, as point-of-care H-FABP tests are available, this strategy might also be appealing in an out-of-hospital context. 8, 9 Indeed, studies have reported improved detection and exclusion of myocardial infarction with early H-FABP assessment when compared with cardiac troponin testing only. [17] [18] [19] [20] [21] [22] However, whether this holds true when H-FABP testing is compared with contemporary high-sensitivity cardiac troponin assays is uncertain, with conflicting results being reported. [23] [24] [25] Our results confirm that the timing of testing in relationship to chest pain onset is very important as the diagnostic accuracy of point-of-care H-FABP versus hs-TnT testing decreases significantly already after 180 min.
Based on the results of this study, it might be interesting to further evaluate point-of-care H-FABP testing in a population of patients presenting with acute chest pain to general practitioners. First, such patients have often a relatively low pre-test probability for ACS and less advanced coronary artery disease. Hypothetically, in such a population, rapid point-of-care testing might perform well to rule out myocardial infarction safely with minimal costs and use of healthcare resources. Importantly, it has been shown that patients presenting with acute chest pain and very low hs-TnT levels (<5 ng/l) can safely be discharged from the emergency department with 99.8% negative predictive value for myocardial infarction. 26 If chest pain onset is acute, point-of-care H-FABP testing may produce similar results with the advantage that it would be also available in an out-of-hospital context. In this study, during the first 3 h after chest pain onset, H-FABP had 94% sensitivity to exclude myocardial infarction at a cut-off of 2.4 µg/l, similar to hs-TnT at a cut-off of 5 ng/l.
Finally, this study confirms the prognostic value of H-FABP levels at the moment of hospital admission. 27, 28 Interestingly, admission H-FABP but not hs-TnT levels were significantly associated with the risk for all-cause mortality. One explanation might be that H-FABP starts to rise more early after onset of a myocardial infarction when compared with cardiac troponin levels, with admission values closer to the peak value. Alternatively, H-FABP may capture better the extent of myocardial ischaemia, even when frank necrosis is absent. 29 
Study limitations
Some limitations should be acknowledged when interpreting the study results. First, this was a single-centre study with limited sample size. Therefore, especially with regard to subgroup analyses, our study might have been underpowered and results should be considered exploratory and hypothesis-generating, asking for confirmation in a larger trial. Second, the diagnostic accuracy of point-of-care H-FABP testing was compared with hs-TnT assessment, with the latter constituting an integral part of the definition of the primary end-point, that is, myocardial infarction. This might have resulted in an underestimation of the diagnostic accuracy of H-FABP versus hs-TnT. However, in the large majority of patients the presence or absence of an intracoronary thrombus was confirmed by coronary angiography. Third, our study was likely underpowered for assessment of all-cause mortality. However, we found a highly significant association of admission H-FABP levels with the risk for allcause mortality and this correlation became even stronger after adjustment for baseline characteristics. Finally, the current study population had a high pre-test probability for ACS, illustrated by a final diagnosis of myocardial infarction made in 63% of cases. This potentially reduces the external validity of the current study to a common emergency department population.
Conclusion
In patients with high pre-test probability for ACS, pointof-care H-FABP testing had lower diagnostic accuracy for myocardial infarction when compared with hs-TnT assessment and did not improve the diagnostic accuracy of the latter when combined testing was performed. However, point-of-care H-FABP testing versus hs-TnT measurements had similar sensitivity and specificity when early assessment within 180 min of chest pain onset was possible. Admission H-FABP was a strong and independent predictor of survival in patients presenting with typical chest pain at the emergency department.
